Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
rapidly progressive steroid resistant focal segmental glomerulosclerosis associated with an inf2 exon 6 variant
Original title: “Rapidly progressive steroid-resistant focal segmental glomerulosclerosis associated with an INF2 exon 6 variant.”
anti cd38 anti cd20 rescue therapy for posttransplant recurrent fsgs
Original title: “Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.”
under enrollment in rare kidney disease trials lessons learned from the privent recurrent fsgs
Original title: “Under-enrollment in rare kidney disease trials: lessons learned from the PRIVENT recurrent FSGS.”
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.
Original title: “Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease”